Investor news Archives - Page 3 of 4

VIGO estimates for the second quarter and the first half of 2023 - revenue growth by 20% y/y in the first half of the year, growing sales in the USA, good prospects for the military segment

VIGO Photonics S.A. (WSE: VGO), a global manufacturer of the most advanced photonic detectors and mid-infrared detection modules as well as semiconductor materials, achieved PLN 37.3 million (+21% y/y) in consolidated revenue in the first half of 2023

Illustration of analytical tools and data visualization. A hand holds a magnifying glass over pie charts and bar graphs. Speech bubbles and a wavy line graph are also present, symbolizing communication and analysis.

The European Commission has approved the amount of state aid up to EUR 102.9 million for the VIGO Photonics project

The European Commission has approved public aid for VIGO Photonics up to EUR 102.85 million for the HyperPIC project.

Videoconference on Q1 2023 financial results with the Management Board of VIGO PHOTONICS

We are pleased to invite you to a videoconference dedicated to the presentation of Company’s Q1 2023 financial results and its development plans.

Illustration of a hand holding a magnifying glass over charts and graphs, including a pie chart and bar graphs. Speech bubbles and a computer window are also visible, symbolizing data analysis and communication.

VIGO Photonics sums up 2022

VIGO Photonics S.A. (WSE: VGO), a global manufacturer of the most advanced mid-infrared photonic detectors, detector modules and semiconductor materials, has published its 2022 annual report.

VIGO estimates for Q1 2023 - growing sales in the USA and Asia, a significant increase in sales in the military segment

/Home / Investor news / Page 3 VIGO estimates for Q1 2023 - growing sales in…

Videoconference on 2022 financial results with the Management Board of VIGO PHOTONICS

We are pleased to invite you to a videoconference dedicated to the presentation of Company’s 2022 financial results and its development plans.

VIGO estimates for Q4 2022 - growing sales in industrial and science & medicine segments despite challenging market conditions